TYK2 Inhibitors
Mar 13, 2026
SOTYKTU Expands Its Reach as Bristol Myers Squibb Lands Key Approval in Psoriatic Arthritis
Summary Bristol Myers Squibb’s SOTYKTU has received FDA approval for adults with active psoriatic arthritis, becoming the first and only TYK2 inhibitor authorized for this indication. The drug extends its reach beyond its 2022 approval for moderate-to-severe plaque psoriasis, reinforcing BMS’s bid to b...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
